Medivir’s fostrox + Lenvima confirm promise of improved outcomes in advanced liver cancer, detailed and mature data presented at ESMO
· Mature results from Medivir’s phase 1b / 2a open label trial of fostrox + Lenvima® confirm improved outcomes in second-line advanced liver cancer with a median time to progression (TTP) of 10.9 months[1] (4.1 – 18.1). · The results showed an objective response (ORR) of 24%, and a median duration of response of 7.0 months. · Detailed safety update reinforces the ability to combine fostrox and Lenvima long-term, only 1 patient discontinuing fostrox due to adverse events. · Medivir’s fostrox (fostroxacitabine bralpamide) is the only orally-administered, liver-targeted inhibitor